Author

R. Debets

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. A. M. Oostvogels· 1 shared A. A. M. van der Veldt· 1 shared A. Gil-Jimenez· 1 shared A. Gutwillig· 1 shared A. Madi· 1 shared A. Trapman-Jansen· 1 shared B. E. Szabados· 1 shared C. Luxenburg· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. M. Oostvogels

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical models

D. Kortleve, D. Hammerl, M. van Brakel, R. Wijers, D. Roelofs, K. Kroese, M. Timmermans, C.-Y. Liao, A. Trapman-Jansen, R. Foekens, J. Michaux, M. de Beijer, S. I. Buschow, J. A. Demmers, M. Kok, , R. Debets

This study identifies ROPN1 as a target for TCR-engineered T-cells effective against TNBC in preclinical models and demonstrates their safety and efficacy.

bioRxiv · Jan 10, 2024 · PreprintImmunology

T Cell-to-Stroma Enrichment (TSE) score: a gene expression metric that predicts response to immune checkpoint inhibitors in patients with urothelial cancer

M. M. Rijnders, J. A. Nakauma-Gonzalez, D. G. J. Robbrecht, A. Gil-Jimenez, H. E. Balcioglu, A. A. M. Oostvogels, M. J. B. Aarts, J. L. Boormans, P. Hamberg, M. S. van der Heijden, B. E. Szabados, G. J. L. H. van Leenders, N. Mehra, J. Voortman, H. M. Westgeest, , M. P. Lolkema

bioRxiv · May 30, 2022 · PreprintCancer Biology

Transient cell-in-cell formation underlies tumor resistance to immunotherapy

A. Gutwillig, N. Santana-Magal, L. Farhat-Younis, D. Rasoulouniriana, A. Madi, C. Luxenburg, J. Cohen, K. Padmanabhan, N. Shomron, G. Shapira, M. Feinmesser, O. Zlotnik, R. Debets, N. E. Reticker-Flynn, P. Rider, Y. Carmi

This study identifies transient cell-in-cell formations as a mechanism enabling tumor resistance to immunotherapy, showing they protect tumor cells from immune and chemotherapy attacks.

bioRxiv · Sep 10, 2020 · PreprintImmunology